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Background: We investigated the additional contribution of mammography to screening accuracy in BRCA1/2 mutation carriers
screened with MRI at different ages using individual patient data from six high-risk screening trials.
Methods: Sensitivity and specificity of MRI, mammography and the combination of these tests were compared stratified for BRCA
mutation and age using generalised linear mixed models with random effect for studies. Number of screens needed (NSN) for
additional mammography-only detected cancer was estimated.
Results: In BRCA1/2 mutation carriers of all ages (BRCA1¼ 1219 and BRCA2¼ 732), adding mammography to MRI did not
significantly increase screening sensitivity (increased by 3.9% in BRCA1 and 12.6% in BRCA2 mutation carriers, P40.05). However,
in women with BRCA2 mutation younger than 40 years, one-third of breast cancers were detected by mammography only.
Number of screens needed for mammography to detect one breast cancer not detected by MRI was much higher for BRCA1
compared with BRCA2 mutation carriers at initial and repeat screening.
Conclusions: Additional screening sensitivity from mammography above that from MRI is limited in BRCA1 mutation carriers,
whereas mammography contributes to screening sensitivity in BRCA2 mutation carriers, especially thosep40 years. The evidence
from our work highlights that a differential screening schedule by BRCA status is worth considering.
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Women with a BRCA1 or BRCA2 mutation have limited choices to
prevent mortality resulting from their 40–80% lifetime risk for
breast cancer (Chen and Parmigiani, 2007). Screening with yearly
MRI from age 25 years onwards, and additional mammography
from age 30 years is recommended in international guidelines
(Mann et al, 2008; Sardanelli et al, 2010; Zonderland et al, 2012;
NICE, 2013), and is estimated to be slightly less effective than
preventive mastectomy (Kurian et al, 2010; Heemskerk-Gerritsen
et al, 2013). Several prospective high-risk screening studies have
evaluated both MRI and mammography (Lord et al, 2007; Warner
et al, 2008) as a screening strategy in high-risk women to improve
screening sensitivity. In the absence of randomised controlled trials
for MRI screening, these screening studies build on evidence that
early detection of breast cancer may confer benefit as shown for
mammography in population screening (Glasziou and Houssami,
2011). The combination of mammography and MRI screening of
BRCA1/2 carriers in most guidelines, from the age of 30 or 40 years
(Mann et al, 2008; Sardanelli et al, 2010; Zonderland et al, 2012;
NICE, 2013), is based on the enhanced sensitivity shown through
this strategy (Lord et al, 2007; Warner et al, 2008), despite
arguments around limitations of mammography. These include
that mammography is relatively sensitive in fatty breasts (generally
in older women) but less sensitive in young women who frequently
have dense breasts. In addition, screening with mammography
could lead to the induction of breast cancer by X-rays at younger
ages (Jansen-van der Weide et al, 2010). Proper repair of DNA
double-strand breaks that are caused by low-dose X-rays is
impaired at any age in both BRCA1 and BRCA2 mutations carriers
(Powell and Kachnic, 2003). This makes BRCA1 and BRCA2
mutation carriers more susceptible than non-carriers, possibly also
at older ages, to the cumulative effect of yearly mammograms.
Given these potential disadvantages of mammography, it is
important to balance the potential benefits and harms of
mammography screening in BRCA1/2 mutation carriers. Hence,
substantial early detection of breast cancer by mammography is
needed to outweigh the potential harm of cancer induction
(Jansen-van der Weide et al, 2010) in BRCA1/2 mutation carriers.
We performed an individual patient data (IPD) meta-analysis
from six prospective MRI screening studies to determine if
mammography screening in BRCA1/2 mutation carriers in
addition to MRI improves screening accuracy, and whether this
effect differs between BRCA1 and BRCA2 gene mutation carriers or
by different age groups.
MATERIALS AND METHODS
An IPD meta-analysis was conducted by pooling individual data
from relevant prospective MRI screening studies (Phi et al, 2014).
Studies were eligible if mammography and MRI breast cancer
sensitivity and specificity were compared in women with a BRCA1/
2 mutation. After searching PubMed, 12 studies met the eligibility
requirements and were sought to contribute to the data (Phi et al,
2014). Six of these provided IPD data (Leach et al, 2005;
Rijnsburger et al, 2010; Trop et al, 2010; Sardanelli et al, 2011;
Passaperuma et al, 2012; Riedl et al, 2015), and were included in
this meta-analysis; the reasons for non-inclusion of some studies
have been reported in our earlier work (Phi et al, 2014). Included
studies were assessed in terms of reporting quality, and were
qualified as high quality (Phi et al, 2014). The data were assembled
and cross-checked with the original publications; inclusion criteria
for analyses were women with a BRCA1/2 mutation, screened
annually with both mammography and MRI. Breast cancer
diagnosis was confirmed by pathology and the absence of breast
cancer at 1 year follow-up (Phi et al, 2014). A summary of the
included studies was reported previously (http://jco.ascopubs.org/
content/33/4/349/T1.large.jpg)
Primary outcome and definition. Primary outcome was sensi-
tivity and specificity of mammography and MRI separately, as well
as combined. Analyses were stratified for mutation type (BRCA1 or
BRCA2) and age in years at screening (40 years and younger,
between 41 and 50 years, over 50 years).
Sensitivity was defined as the number of breast cancers detected
by a screening modality (MRI or mammography, or the
combination) from the total number of breast cancers diagnosed
during the study course. Specificity of a screening modality was
defined as the number classified as true negative by the test from
the total number of true-negative plus false-positive results.
A true positive was defined as a positive screening result
(BI-RADS 0, 3, 4, 5) followed by a pathology-proven breast cancer.
A false positive was defined as a positive screening result (BI-RADS
0, 3, 4, 5) not followed by a pathology-proven breast cancer within
1 year of follow-up. A true negative was defined as a negative
screening result (BI-RADS 1, 2) not followed by pathology-proven
breast cancer within 1 year of follow-up. A false-negative case was
defined as a negative screening result (BI-RADS 1, 2) followed by a
pathology-proven breast cancer within 1 year of follow-up.
Statistical analysis. Stratified by BRCA status and age group,
descriptive statistics of the characteristics of the women and their
breast cancer were provided. Breast cancer incidence was
calculated per 1000 woman-years. The related 95% confidence
intervals (CIs) were computed, assuming the incidence follows a
Poisson distribution. To compare differences between groups in
proportion of DCIS, invasive tumour size and grade, w2 tests or
Fisher’s exact tests were applied.
To estimate the sensitivity and the specificity of the screening
modalities, repeated screening results were summarised to form
binomial counts for each woman. For each woman, the number of
true-positive and true-negative screens per modality, and the
number of total screening visits with or without breast cancer
detected were counted. In this way, binomial counts per modality
were calculated and analysed, taking into account that each woman
was her own control. As the dependent variable was assumed to
follow a binomial distribution, a generalised linear mixed model
with logit link function was applied, and the binomial proportions
were modelled as a function of modality and BRCA status and
conducted separately for sensitivity and specificity. Studies were
entered as random-effect variables and study heterogeneities were
assumed to depend on modality. The analyses were conducted
separately for each age group. To test the differences between the
sensitivities and specificities for the three modalities, Wald tests
were applied, where the hypothesis was that the difference between
the two proportions under study was 0.
The number of mammographic screens that would have been
needed (NSN) to detect one breast cancer that was missed by MRI
was calculated, and stratified according to BRCA mutation, age
group and screening round (first or subsequent round). All
analyses were performed using SAS 9.4 (SAS Institute, Cary, NC,
USA). P-values o0.05 were considered statistically significant.
RESULTS
Study population and breast cancer characteristic. The analyses
were based on 1951 BRCA1/2 mutation carriers with 6085 woman-
years of follow-up (Table 1). There was no significant difference in
cancer risk between BRCA1 and BRCA2 mutation carriers.
Five breast cancers were diagnosed before the age of 30 in
BRCA1 mutation carriers, and none in BRCA2 mutation carriers.
The proportion of DCIS differed between BRCA groups in age
groups older than 40 years, as shown in Table 1.
Sensitivity and specificity of MRI and mammography in BRCA1
mutation carriers. In BRCA1 mutation carriers, there were no
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statistically significant differences in sensitivity and specificity
between mammography and MRI combined compared with MRI
alone. Sensitivity of the combination was higher compared with
that of MRI alone in all age groups (agep40: 86.8% (63.1–96.2) vs
77.5% (57–90), P¼ 0.441; age 41–50: 94.1% (74.5–98.9) vs 93.1%
(70.8–98.7), P¼ 0.895; age450: 89.3% (71.3–96.6) vs 89.1% (54.8–
98.2), P¼ 0.986). Combining mammography and MRI decreased
specificity compared with MRI screening alone in all age groups
(age p40 years: 81% (73.9–86.5) vs 84.3% (78.7–88.7), P¼ 0.409;
age 41–50 years: 77.2% (70.5–82.8) vs 82.9% (77.9–87), P¼ 0.135;
age450 years: 87.4% (79.3–92.6) vs 89.9% (82.6–94.3), P¼ 0.566).
Further results are shown in Table 2.
Sensitivity and specificity of MRI and mammography in BRCA2
mutation carriers. In BRCA2 carriers, there were no significant
differences in sensitivity or specificity between combined mammo-
graphy and MRI and MRI alone in all age groups. Sensitivity of the
combination was higher compared with that of MRI alone in all
age groups (age p40 years: 87.2% (56.1–97.3) vs 52.7% (27.2–
76.8), P¼ 0.075; age 41–50 years: 91.2% (70.4–97.9) vs 86.4%
(58.2–96.7), P¼ 0.646; age 450 years: 94.1% (67.5–99.2) vs 85%
(43.7–97.7), P¼ 0.474). Combining mammography and MRI
decreased specificity compared with MRI screening alone in all
age groups (age p40 years: 75.3% (66.6–82.4) vs 80.2%
(72.9–85.8), P¼ 0.351; age 41–50 years: 80% (73.3–85.3) vs 86%
(81.1–89.8), P¼ 0.105; age 450 years: 88.6% (80.7–93.6) vs 91.1%
(84–95.2), P¼ 0.565). Further results are shown in Table 2.
Mammography contribution to screening sensitivity in BRCA1
mutation carriers. In BRCA1 carriers overall, adding mammo-
graphy to MRI screening increased sensitivity by roughly 4–92.5%
(Table 2) (P¼ 0.553). In the p40 years age group, the addition of
mammography increased sensitivity by 9.3% (Table 2). Without
mammography, 3 of 46 (6.5%) breast cancers, including 2 DCIS,
would not have been detected (Table 3) in this subgroup. In the
41–50 years group, additional mammography increased sensitivity
by only 1% (Table 2), detecting 1 DCIS (2.7%) (Table 3). Similarly,
in the 450 years age group, mammography detected one
additional cancer (3.4% of cancers) (Table 3).
Mammography contribution to screening sensitivity in BRCA2
mutation carriers. In BRCA2 carriers, adding mammography to
Table 1. Overview of women (n¼1951) and their BCs (n¼184)a
All ages Age p40 years Age 41–50 years Age over 50 years
BRCA1 BRCA2 BRCA1 BRCA2 BRCA1 BRCA2 BRCA1 BRCA2
Women (N) 1219 732 605 301 482 308 310 228
Follow-up time
(woman-years)
3840 2245 1691 749 1216 812 895 673
BC (N) 112 72 46 18 38 37 28 17
BC risk ((95% CI) 29.2 (24–35.1) 32.1 (25.1–.40.4) 27.2 (19.9–36.3) 24 (14.2–38) 31.3 (22.1–42.9) 45.6 (32.1–62.8) 31.3 (20.8–45.2) 25.3 (14.7–40.4)
DCISb 15 (13.4%) 22 (30.6%) 9 (19.6%) 3 (16.7%) 3 (7.9%) 13 (35.1%) 3 (10.7%) 6 (35.3%)
Invasive cancersc 97 (86.6%) 50 (69.4%) 37 (80.4%) 15 (83.3%) 35 (92.1%) 24 (64.9%) 25 (89.3%) 11 (64.7%)
Invasive o1 cm 26 (26.8%) 17 (34.0%) 8 (21.6%) 2 (13.3%) 10 (28.6%) 11 (45.8%) 8 (32.0%) 4 (36.4%)
Invasive 1–2 cm 35 (36.1%) 12 (24.0%) 13 (35.1%) 5 (33.3%) 8 (22.9%) 3 (12.5%) 14 (56.0%) 4 (36.4%)





41(36.6%) 39 (54.2%) 17 (37.0%) 5 (27.8%) 13 (34.2%) 24 (64.9%) 11 (39.3%) 10 (58.8%)
Abbreviations: BC¼breast cancer; DCIS¼ductal carcinoma in situ. BC risk was expressed per 1000 woman-years of follow-up.
aStratified by age at screening and for BRCA1 or BRCA2 mutation status
bP¼ 0.0095 comparing DCIS rate between BRCA1 and BRCA2 mutation carriers at the age 41–50 years, and for all ages, comparing DCIS rate between BRCA1 and BRCA2 mutation carriers,
P¼ 0.0077.
cNine cases with missing histological subtype were considered as invasive BCs.



































BRCA1 (n¼ 112) 39 35.7 (25.9–46.9) 93.8 (89.3–96.5) 92 88.6 (73.4–95.6) 84.4 (78.7–88.8) 98 92.5 (80.1–97.4) 80.4 (72.8–86.2)
BRCA2 (n¼ 72) 31 44.6 (31.9–58) 93.4 (88.4–96.3) 53 80.1 (58.9–91.9) 85.3 (79.6–89.6) 64 92.7 (79.3–97.7) 80.5 (72.8–86.4)
p40 BRCA1 (n¼ 46) 18 39.1 (26.2–53.9) 94.9 (91.2–97.1) 34 77.5 (57–90) 84.3 (78.7–88.7) 38 86.8 (63.1–96.2) 81 (73.9–86.5)
BRCA2 (n¼ 18) 10 55.6 (32.9–76.1) 92.3 (86.6–95.7) 9 52.7 (27.2–76.8) 80.2 (72.9–85.8) 15 87.2 (56.1–97.3) 75.3 (66.6–82.4)
41–50
BRCA1 (n¼ 38) 13 34.2 (21–50.5) 91.5 (86.7–94.6) 34 93.1 (70.8–98.7) 82.9 (77.9–87) 35 94.1 (74.5–98.9) 77.2 (70.5–82.8)
BRCA2 (n¼ 38) 14 37.8 (22.7–55.5) 92 (87–95.2) 30 86.4 (58.2–96.7) 86 (81.1–89.8) 33 91.2 (70.4–97.9) 80 (73.3–85.3)
450
BRCA1 (n¼ 28) 8 29.4 (12.8–54.2) 96.8 (91.9–98.8) 24 89.1 (54.8–98.2) 89.9 (82.6–94.3) 25 89.3 (71.3–96.6) 87.4 (79.3–92.6)
BRCA2 (n¼ 17) 7 45.5 (19.3–74.4) 97.4(92.8–99.1) 14 85 (43.7–97.7) 91.1 (84–95.2) 16 94.1 (67.5–99.2) 88.6 (80.7–93.6)
Abbreviations: BC¼breast cancer; CI¼ confidence interval; MRI¼magnetic resonance imaging.
aStratified by age at screening and by BRCA1 or BRCA2 mutation status.
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MRI screening increased sensitivity by 12.6–92.7% (Table 2)
(P¼ 0.154). In the p40 age group, additional mammography
increased sensitivity by 34.5% (Table 2). Without mammography,
6 of 18 cancers (33.3%), including 2 DCIS, would not have been
detected in this young age group (Table 3). In women aged 41–50
years, adding mammography nonsignificantly increased sensitivity
by nearly 5% (Table 2) and detected 3 cancers, including 1 DCIS,
which were not detected by MRI (8.1% of cancers). In the 450
years age group, screening sensitivity increased nonsignificantly by
B9% (Table 2), and mammography detected two cancers (11.8%)
that were not detected by MRI, including 1 DCIS.
Number of mammographic screens needed to detect one breast
cancer not detected by MRI. For the first screening round, the
NSN for mammography to detect one breast cancer not detected
by MRI was 527 for women with a BRCA1 mutation and 94 for
women with a BRCA2 mutation for all ages (Table 4). For
subsequent screening rounds, the NSN for mammography to
detect an additional breast cancer for women with a BRCA1
mutation (717 screens) was roughly three times that for women
with a BRCA2 mutation (231 screens).
DISCUSSION
This IPD meta-analysis has identified differences in the contribu-
tion of mammography to screening high-risk women according to
age and mutation status. Adding mammography to MRI screening
in BRCA1 mutation carriers leads to a very modest increase in
sensitivity of 3.9% among 112 breast cancers (P¼ 0.553), and a
small decrease in specificity (by 4%, P¼ 0.154). One invasive
cancer and 2 DCIS (6.5%) of the 46 BRCA1 breast cancers detected
before the age of 40 years, and only 1 DCIS and 1 invasive cancer
o1 cm (3%) in a total of 66 BRCA1 breast cancers would not have
been detected at that screen after the age of 40 years. The
percentage of early-stage (DCIS or o1 cm invasive) cancers
detected with both MRI and mammography screening of 36.6%
Table 3. Mammography-only detected breast cancers stratified for BRCA1 or BRCA2 mutation status
No. Mutation status Age at diagnosis Tumour type Invasive tumour size Invasive tumour grade Screening round
1 BRCA1 31 DCIS — — 2
2 BRCA1 33 DCIS — — 2
3 BRCA1 40 IDC 1–2 cm Grade 3 1
4 BRCA1 42 DCIS — — 3
5 BRCA1 56 IDC o1 cm Grade 3 4
1 BRCA2 36 DCIS — — 1
2 BRCA2 37 DCIS — — 1
3 BRCA2 35 IDC o1 cm Grade 2 4
4 BRCA2 36 IDC 1–2 cm Grade 3 1
5 BRCA2 37 ILC 2–5 cm Grade 2 1
6 BRCA2 39 Other NA NA 3
7 BRCA2 42 DCIS — — 4
8 BRCA2 53 DCIS — — 2
9 BRCA2 44 ILC 45 cm 3 1
10 BRCA2 47 ILC 45 cm 2 5
11 BRCA2 51 NA NA NA 1
Abbreviations: DCIS¼ductal carcinoma in situ; IDC¼ invasive ductal; ILC¼ invasive lobular; NA¼not applicable.








BC only detected by
mammography
NSN for mammography to detect one BC
missed by MRI
First screening round
BRCA1 All ages 45 1053 2 527
Age o40 19 555 2 278
41–50 14 304 0 NA
Age 450 12 194 0 NA
BRCA2 All ages 18 564 6 94
Age o40 10 221 4 55
41–50 10 204 1 204
Age 450 8 139 1 139
Subsequent (repeat) screening rounds
BRCA1 All ages 67 2150 3 717
Age o40 27 775 1 775
41–50 23 797 1 797
Age 450 17 578 1 578
BRCA2 All ages 54 1155 5 231
Age o40 8 281 2 141
41–50 27 444 2 222
Age 450 9 430 1 430
Abbreviations: BC¼breast cancer; MRI¼magnetic resonance imaging; NA¼ not applicable; NSN¼ number of screens needed.
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(41 out of 112) would decrease by 3.6% (37 out of 112) if
mammography was not be performed. Using combined MRI and
mammography, 63.4% of the detected cancers were invasive and
41 cm, with 0.9% of these detected by mammography only. To
detect one breast cancer missed by MRI, we estimated that 527
screens for the first screening round and 717 screens for
subsequent rounds with mammography would be needed.
The contribution of mammography above MRI to screening
sensitivity in the 72 BRCA2 mutation carriers was 12.6% (P40.05).
Additional mammography in BRCA2 mutation carriers also
decreased the specificity. Without mammography one-third of
breast cancers would not have been detected in BRCA2 mutation
carriers aged 40 years and younger, but this proportion was 9.3% in
those older than 40 years. We estimate that the percentage
of BRCA2 cancers detected at very early stage (DCIS or invasive
o1 cm) with combined MRI and mammography screening of
54.2% (39 out of 72) would decrease to 47.2% (34 out of 72)
without mammography. Only 94 screens at first round and
231 screens at subsequent rounds of mammography screening
are needed to detect a breast cancer missed by MRI.
Without mammography, four advanced-stage cancers (4 out of
72 cancers, 5.6%) would have been missed in BRCA2 carriers.
An advantage of mammography over MRI has been the ability
to detect DCIS by visualising microcalcifications. The proportion
of DCIS is larger for women with a BRCA2 mutation than for
women with a BRCA1 mutation, thus differences in histology
distributions in BRCA-associated breast cancers may account
for our findings (Heijnsdijk et al, 2012). There might also be
BRCA mutation-specific differences in tumour phenotypes that
also contribute to differences in screen detection. The modest
additional value of digital-only mammography to current MRI
screening of BRCA1 mutation carriers was recently shown in a
retrospective study (Obdeijn et al, 2014). Only 2 (2%) DCIS of 94
breast cancers were detected by mammography alone, none in
women aged below 40 years and no invasive cancers. Importantly,
in this retrospective study with recent data MRI screening detected
67% of the breast cancers detected as DCIS oro1 cm, considerably
more than the 41–44% published for the Dutch, UK and Canadian
studies of our IPD meta-analyses (Rijnsburger et al, 2010;
Passaperuma et al, 2012; Evans et al, 2014) or 36.6% of this IPD
meta-analysis.
It could be argued that at the time the studies forming our IPD
analyses were conducted, radiologists might not have had extensive
experience with breast MRI screening. Most likely, both a learning
curve, as expected for any new screening modality, and improved
techniques explain the relatively improved MRI sensitivities in
more recent studies. A learning curve for MRI screening accuracy
in high-risk women was evident for the Canadian study, in
particular for DCIS detection (Warner et al, 2011). However, in a
previous report in this study population (Phi et al, 2014), the
sensitivity of each of MRI and mammography fluctuated over the
years, and heterogeneity was evident across different studies
possibly masking any potential effect of timeframe (Phi et al, 2014).
A cohort study from the Netherlands showed that digital
mammography had higher sensitivity compared with studies
reporting film mammography (and a transition to digital)
(Obdeijn et al, 2014). However, in the Italian HIBCRIT-1 Study,
transition from film screen to digital mammography (resulting in
screening with roughly equal mix of film screen and digital) did
not increase mammography sensitivity in high-risk women
(Sardanelli et al, 2011). Newer mammography technologies such
as tomosynthesis (3D mammography), which have better screening
sensitivity than standard mammography (Houssami et al, 2014),
have not yet been compared with MRI screening of BRCA carriers.
This lacking evidence in high-risk screening is worthy of research
effort but would still imply increased ionising radiation from
tomosynthesis (Svahn et al, 2014).
In contrast to benefits of possible earlier breast cancer detection,
there are also possible harmful effects of additional mammography
as outlined in the Introduction. Two-fold increase in breast cancers
in BRCA1/2 mutation carriers after exposure to 4 or more
radiographs, compared with non-exposure, was significant below
age 30 years (HR¼ 1.9 (95% CI: 1.2–3.0), but not at 30–39 years
(Pijpe et al, 2012). Two other studies did not demonstrate tumour
induction in BRCA1/2 mutation carriers by screening mammo-
graphy or low-dose contralateral irradiation from breast-conser-
ving treatment (Pierce et al, 2000; Narod et al, 2006). However, this
may have been because of modest follow-up time in these studies,
with consideration that latency time for radiation-induced breast
cancer is 10–15 years (Travis et al, 2005; Jansen-van der Weide
et al, 2010).
From two meta-analyses based on retrospective studies, the
estimated cumulative risk of breast cancer by the age of 70 years
vary from 57% (95% CI: 47–66%) to 65% (95% CI: 44–78) in
women with a BRCA1 mutation and from 45% (95% CI: 31–56%)
to 49% (95% CI: 40–57) in women with a BRCA2 mutation
(Antoniou et al, 2003; Chen and Parmigiani, 2007). In this IPD
meta-analysis, we combined IPD from six prospective studies,
making this the largest analysis in the world of prospectively
collected screening data on BRCA1/2 mutation carriers, although
numbers are modest in some subgroups. We did not observe a
significant difference in the risk of breast cancer between BRCA1
and BRCA2 mutation carriers given a relatively small sample of
breast cancers in the IPD data set. Although data from six studies
could not be included, this only resulted in B716 women with
BRCA1/2 mutations (36 breast cancers) not being included in the
IPD (Kuhl et al, 2005, 2010; Lehman et al, 2005, 2007; Hagen et al,
2007; Weinstein et al, 2009). As these studies showed generally
similar results for the added value of mammography to MRI, we
would not expect their non-inclusion to have substantially altered
our estimates.
This work differs from our recent report using the same IPD data
(Phi et al, 2014) because the present analyses focus on screening
outcomes by BRCA status and age group to determine mammo-
graphy’s contribution. Based on our findings, the additional
detection from mammography in BRCA1 mutation carriers who
receive MRI screening is minimal, and might not outweigh potential
disadvantages (potential cancer induction by radiation, false-positive
results). It may be reasonable, on the basis of this collective evidence,
to consider potential omission of mammography screening in
BRCA1 mutation carriers or to open discussion on its potential
omission given its limited contribution. In BRCA2mutation carriers,
the contribution of mammography above MRI is more evident.
Different screening recommendations for these two groups of
women defined by BRCA mutation status should be considered on
the basis of the evidence we report, factoring the estimated
contribution of mammography and its potential harms.
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